Embecta (Nasdaq:EMBC) today posted fourth-quarter financial results that proved mixed compared to the consensus forecast on Wall Street. Shares of EMBC remained unmoved at $14.64 apiece in pre-market trading today. The Parsippany, New Jersey-based BD Diabetes spinoff reported profits of $26.4 million. That equals 45¢ per share on sales of $264 million for the three […]
embecta
Embecta expands partnership with Direct Relief to support diabetes initiatives on World Diabetes Day
Embecta (Nasdaq:EMBC) today announced an expansion of its partnership with Direct Relief to mark World Diabetes Day. Today, Nov. 14, is World Diabetes Day, which marks the birthday of Sir Frederick Banting. Banting discovered the insulin hormone along with Charles Herbert Best in 1922. It also lands during the American Diabetes Association’s National Diabetes Awareness […]
What diabetes tech companies are doing on World Diabetes Day 2025
Once again, World Diabetes Day, celebrated on Nov. 14 every year, has come around, highlighting new initiatives in the diabetes tech space. The date marks the birthday of Sir Frederick Banting. Banting discovered the insulin hormone along with Charles Herbert Best in 1922. It also lands during the American Diabetes Association’s National Diabetes Awareness Month. […]
Analysts label Embecta ‘undervalued’ and poised for growth
BTIG analysts maintain a “Buy” rating for Embecta (Nasdaq:EMBC) after meetings with company officials highlighted plans for growth. Marie Thibault, Sam Eiber and Alexandra Pang hosted Embecta CEO Devdatt Kurdikar and Head of Investor Relations Pravesh Khandelwal this week. Following the in-person and virtual meetings, the analysts maintain confidence in the former BD Diabetes unit’s […]
Embecta stock gets a boost on Q3 beats, raised guidance
Embecta (Nasdaq:EMBC) shares ticked up today on third-quarter results that came in ahead of the consensus forecast on Wall Street. Shares of EMBC 17% to $12.12 apiece in early-morning trading today. The Parsippany, New Jersey-based diabetes technology company — which spun off from BD three years ago — reported profits of $45.5 million. That equals […]
The 10 largest diabetes technology companies in the world
What has changed in the last year as diabetes technology developers continue to innovate and advance their offerings? We are seeing the industry form an intriguing niche at the intersection of medtech and consumer devices. Various companies around the world are delivering numerous options when it comes to the type of technology they want to […]
Embecta eyes shift from insulin delivery to broader medical supplies focus
Embecta (Nasdaq:EMBC) today revealed its phased plan to create value and shift priorities toward broader medical applications. The pure-play diabetes technology company has endured ups and downs since its 2022 spin-off from BD. That includes an FDA approval for a disposable insulin patch pump system in September 2024, only to be followed by the discontinuation […]
Embecta to undergo further restructuring, lowers guidance amid tariff impact
Embecta (Nasdaq:EMBC) stock was down today after news of restructuring and mixed second-quarter results. Shares of EMBC were down more than 8% to $12.12 apiece near the close of trading today. While the company continues to work through the discontinuation of its insulin patch pump program — the plan for which it says is substantially […]
Embecta shares study highlighting need for training, standardization in insulin delivery
Embecta (Nasdaq:EMBC) announced a new publication introducing best practices for insulin injection techniques and education. The publication in the Mayo Clinic Proceedings introduces the FITTER Forward Expert Recommendations. These best practices, authored by a panel of 16 diabetes specialists from 13 countries, highlight the critical need for improved training and standardization in insulin delivery. It […]
Embecta stock rises on Street-beating Q1, patch pump continuation remains on track
Embecta (Nasdaq:EMBC) shares ticked up before hours today on first-quarter results that came in ahead of the consensus forecast. Shares of EMBC rose 1.65% to $18.50 apiece in pre-market trading today. The Parsippany, New Jersey-based diabetes technology company reported profits of $157.1 million. That equals $0 per share on sales of $261.9 million for the […]
